Anne Osdoit

Anne Osdoit has an extensive work experience in the medical and healthcare industries. Anne began their career in 2005 as an Applications Specialist at Mauna Kea Technologies, then progressed to Clinical Affairs Manager and Director of Marketing and Clinical Affairs. In 2014, they became an Independent Board Director at FeetMe and a Partner at MD Start. In 2015, they were President and Board Director (formerly CEO) of SafeHeal and an Independent Board Director at CardioLogs until the company's exit. In 2016, they joined Sofinnova Partners as a Partner, and in 2017 they became a Board Director (formerly CEO) at AblaCare. In 2020, they were appointed Chief Executive Officer of both Moon Surgical and Gradient Denervation Technologies.

Anne Osdoit received their Master of Science (MS) in Biomedical/Medical Engineering from The Johns Hopkins University from 2003 to 2004. Anne then received their Master of Science (MS) in Engineering from \u00c9cole Polytechnique from 2000 to 2003. In 2006 to 2007, they attended Pierre and Marie Curie University where they received their DIU CESAM - Centre d'Etudes Statistiques Appliqu\u00e9es \u00e0 la M\u00e9decine in Biostatistics. In 2014, they attended The London School of Economics and Political Science (LSE) and completed the Corporate Finance & Strategy - Executive summer school program in Finance, General.